GATEWAY BIOTECHNOLOGY, INC — Department of Defense SBIR: MEDICAL RESEARCH AND DEVELOPMENT CONTRACT DHA SBIR PH II, PROPOSAL NO. H2S-0048, TITLED: "
GATEWAY BIOTECHNOLOGY, INC — SBIR award from Department of Defense.
SBIR award competitive context
- Public SBIR obligation from Department of Defense to GATEWAY BIOTECHNOLOGY, INC. Use agency + tech-domain links below to map the broader competitive field.
- At $1,949,999, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Gateway Biotechnology received nearly $1.95 million from the Defense Health Agency for an SBIR Phase II project to develop a new drug called GW-TT2 for treating tinnitus. The award supports medical research and development of this pharmaceutical product.
- Amount
- $1,949,999
- Agency
- Department of Defense · Defense Health Agency
- Program / Phase
- SBIR
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- OH
- Period
- 2023-09-18 → 2027-08-23
Technology domains
Description
MEDICAL RESEARCH AND DEVELOPMENT CONTRACT DHA SBIR PH II, PROPOSAL NO. H2S-0048, TITLED: "GW-TT2, A NEW DRUG PRODUCT FOR TINNITUS"